Primaquine Therapy for Malaria
Identifieur interne : 001F19 ( Main/Exploration ); précédent : 001F18; suivant : 001F20Primaquine Therapy for Malaria
Auteurs : J. Kevin Baird [États-Unis] ; Stephen L. Hoffman [États-Unis]Source :
- Clinical Infectious Diseases [ 1058-4838 ] ; 2004.
Abstract
Primaquine is the only available drug for preventing relapse of malaria, and confusion surrounds its use. This review examines the wide range of clinical applications of primaquine described in the medical literature between 1946 and 2004. The risk of relapse of Plasmodium vivax malaria without primaquine therapy ranged from 5% to 80% or more, depending largely upon geographic location. Supervision of therapy profoundly impacts the risk of relapse, and almost all reports of malaria resistant to primaquine are associated with lack of such supervision. We nonetheless suspect that there is widespread resistance to the standard course of primaquine therapy, which is 15 mg primaquine base daily for 14 days. Clinical evidence confirms that a course of 15 mg daily for just 5 days, a regimen widely used in areas where malaria is endemic, has no discernible efficacy. This review supports a recommendation for a regimen of 0.5 mg/kg primaquine daily for 14 days, on the basis of superior efficacy and good tolerability and safety in nonpregnant persons without glucose-6-phosphate dehydrogenase deficiency.
Url:
DOI: 10.1086/424663
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B27
- to stream Istex, to step Curation: 000B27
- to stream Istex, to step Checkpoint: 000D60
- to stream Main, to step Merge: 001F34
- to stream Main, to step Curation: 001F19
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Primaquine Therapy for Malaria</title><author><name sortKey="Baird, J Kevin" sort="Baird, J Kevin" uniqKey="Baird J" first="J. Kevin" last="Baird">J. Kevin Baird</name></author><author><name sortKey="Hoffman, Stephen L" sort="Hoffman, Stephen L" uniqKey="Hoffman S" first="Stephen L." last="Hoffman">Stephen L. Hoffman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0CDF1031E6C7E5D87173AEEC880DEB5CDA6C7D81</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1086/424663</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-QXKCDNTC-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B27</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B27</idno><idno type="wicri:Area/Istex/Curation">000B27</idno><idno type="wicri:Area/Istex/Checkpoint">000D60</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D60</idno><idno type="wicri:doubleKey">1058-4838:2004:Baird J:primaquine:therapy:for</idno><idno type="wicri:Area/Main/Merge">001F34</idno><idno type="wicri:Area/Main/Curation">001F19</idno><idno type="wicri:Area/Main/Exploration">001F19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Primaquine Therapy for Malaria</title><author><name sortKey="Baird, J Kevin" sort="Baird, J Kevin" uniqKey="Baird J" first="J. Kevin" last="Baird">J. Kevin Baird</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>US Naval Medical Research Center Detachment, Lima, Peru, Rockville</wicri:cityArea></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Hoffman, Stephen L" sort="Hoffman, Stephen L" uniqKey="Hoffman S" first="Stephen L." last="Hoffman">Stephen L. Hoffman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>US Naval Medical Research Center Detachment, Lima, Peru, Rockville</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical Infectious Diseases</title><title level="j" type="abbrev">Clinical Infectious Diseases</title><idno type="ISSN">1058-4838</idno><idno type="eISSN">1537-6591</idno><imprint><publisher>The University of Chicago Press</publisher><date when="2004-11-01">2004</date><biblScope unit="vol">39</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1336">1336</biblScope><biblScope unit="page" to="1345">1345</biblScope></imprint><idno type="ISSN">1058-4838</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1058-4838</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Primaquine is the only available drug for preventing relapse of malaria, and confusion surrounds its use. This review examines the wide range of clinical applications of primaquine described in the medical literature between 1946 and 2004. The risk of relapse of Plasmodium vivax malaria without primaquine therapy ranged from 5% to 80% or more, depending largely upon geographic location. Supervision of therapy profoundly impacts the risk of relapse, and almost all reports of malaria resistant to primaquine are associated with lack of such supervision. We nonetheless suspect that there is widespread resistance to the standard course of primaquine therapy, which is 15 mg primaquine base daily for 14 days. Clinical evidence confirms that a course of 15 mg daily for just 5 days, a regimen widely used in areas where malaria is endemic, has no discernible efficacy. This review supports a recommendation for a regimen of 0.5 mg/kg primaquine daily for 14 days, on the basis of superior efficacy and good tolerability and safety in nonpregnant persons without glucose-6-phosphate dehydrogenase deficiency.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Baird, J Kevin" sort="Baird, J Kevin" uniqKey="Baird J" first="J. Kevin" last="Baird">J. Kevin Baird</name></region><name sortKey="Hoffman, Stephen L" sort="Hoffman, Stephen L" uniqKey="Hoffman S" first="Stephen L." last="Hoffman">Stephen L. Hoffman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0CDF1031E6C7E5D87173AEEC880DEB5CDA6C7D81
|texte= Primaquine Therapy for Malaria
}}
| This area was generated with Dilib version V0.6.33. |  |